The present study describes the synthesis, characterization, antileishmanial and antiplasmodial activities of novel diimine/(2,2′-bipyridine (bipy), 1,10-phenanthroline (phen), 4,4′-methylbipyridine (Me-bipy) and 4,4′-methoxybipyridine (MeO-bipy)/phosphine/ruthenium(II) complexes containing lapachol (Lap, 2-hydroxy-3- H NMR, and cyclic voltammetry. The Ru(III) complex, [RuCl 2 (Lap)(dppb)], was also characterized by the EPR technique. The structure of the complexes [Ru(Lap)(PPh 3 ) 2 (bipy)]PF 6 and [RuCl 2 (Lap)(dppb)] was elucidated by X-ray diffraction. The evaluation of the antiparasitic activities of the complexes against Leishmania amazonensis and Plasmodium falciparum demonstrated that lapachol-ruthenium complexes are more potent than the free lapachol. The [RuCl 2 (Lap)(dppb)] complex is the most potent and selective antiparasitic compound among the five new ruthenium complexes studied in this work, exhibiting an activity comparable to the reference drugs.
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Introduction
Leishmaniasis and malaria are diseases caused by protozoan parasites and are characterized by high morbidity. It is estimated that leishmania disease causes about seventy thousand deaths annually and malaria kills around 1 million children only in Africa [1] . The first line treatment for leishmaniasis still relies on the use of pentavalent antimonials, although other drugs are also used for the treatment of Leishmania infection, such as pentamidine isethionate, amphotericin B and miltefosine [2, 3] . Malaria treatment relies on the use of quinolinebased drugs, such as chloroquine, primaquine and mefloquine, as well as antifolates and artemisinin derivatives, depending on the parasite's susceptibility [4] . Common problems with these antiparasitic drugs are severe side effects and development of drug resistance. Based on this scenery, the research of new active compounds against these parasites is pivotal.
The Tabebuia genus, belonging to the bignoniaceae plant family, is widely used in the traditional medicine in South America [5, 6] . Among the active secondary metabolites present in this genus, 2-hydroxy-3-(3-methyl-2-buthenyl)-1,4-naphthoquinone (lapachol, Fig. 1 ) is one of the most studied. Lapachol is endowed with anticancer and antimicrobial properties [7, 8] . Because of its antiproliferative activity, lapachol has been employed as a prototype for the design and synthesis of new anticancer and antimicrobial agents. This has led to the identification of fewer lapachol derivatives with an enhanced activity [9] [10] [11] [12] .
Like other naphthoquinones [13, 14] , lapachol is a feasible ligand for the preparation of coordinating or organometallic compounds. In fact, there are some findings showing that lapachol-metal complexes are biologically more active than the free molecule [15] [16] [17] [18] . Ruthenium complexes are considered to be one of the most promising types of metal compounds for cancer treating, due its interesting chemical properties, such as: versatility in ligand exchange, octahedral geometry and variability of oxidation states [19, 20] . Recently it was observed that the lapachol-Ru(II) complex is a more potent anticancer agent than lapachol-Os(II) and Rh(III) complexes [18] , suggesting that the use of ruthenium is promising to improve the biological activity of lapachol.
Therefore, the present study describes the synthesis, characterization, antileishmanial and antiplasmodial activities of novel diimines (2,2′-bipyridine (bipy), 1,10-phenantroline (phen), 4,4′-methylbipyridine (Me-bipy) and 4,4′-methoxybipyridine (MeO-bipy) and monophosphine ruthenium(II) and (III) complexes containing lapachol as a bidentate ligand.
Experimental section

Materials for synthesis
Solvents were purified by standard methods. All chemicals used were of reagent grade or comparable purity. The RuCl 3 •3H 2 O was purchased from Degussa or Aldrich. The ligands 1,4-bis(diphenylphosphino)butane (dppb), triphenylphosphine (TPP), bipy, Me-bipy, MeO-bipy and phen were used as received from Aldrich.
Instrumentation
Elemental analyses were performed in a Fisons EA 1108 model (Thermo Scientific). The IR spectra of the powder complexes were recorded using CsI pellets in the 4000-200 cm − 1 region in a Bomen- 
X-ray crystallography
Blue single crystals of complexes (1) and (5) were grown by slow evaporation of a dichloromethane/n-hexane solution. X-ray diffraction experiments were carried out using a suitable crystal mounted on glass fiber, and positioned on the goniometer head. Intensity data were measured with the crystal at room temperature on an EnrafNonius Kappa-CCD diffractometer with graphite monochromated MoKα radiation (λ = 0.71073 Å). The cell refinements were performed using the software Collect [21] and Scalepack [22] , and the final cell parameters were obtained on all reflections. Data reduction was carried out using the software Denzo-SMN and Scalepack [22] . The structures were solved by the Direct method using SHELXS-97 [15] and refined using the software SHELXL-97 [23] . A Gaussian method implemented was used for the absorption corrections [24] . Non-hydrogen atoms of the complexes were unambiguously located, and a full-matrix, leastsquare refinement of these atoms with anisotropic thermal parameters was carried out. The aromatic C\H hydrogen atoms were positioned stereochemically and were refined with fixed individual displacement parameters [U iso (H) = 1.2 U eq (Csp 2 )] using a riding model with an aromatic, C\H bond length fixed at 0.93 Å. Methylene groups of the dppb ligand in the complex (5), and methine group of the lapachol were set as isotropic with a thermal parameter 20% greater than the equivalent isotropic displacement parameter of the atom to which each one was bonded, whereas methyl groups were set with U iso (H) values of 1.5U eq (C methyl ). Tables were generated by WinGX [25] and the structure representations by ORTEP-3 [18] and MERCURY [21] . The main crystal data collections and structure refinement parameters for (1) and (5) are summarized in Table 1 .
Synthesis
All the solvents used in this work were of reagent quality and used without further purification. Lapachol was obtained according to the procedure described in [24] . The precursors cis-[RuCl 2 (PPh 3 ) 2 (X-bipy)] (X = H, methyl (Me) and methoxy (MeO)) and cis-[RuCl 2 (PPh 3 ) 2 (phen)] were prepared according to literature [26, 27] . Typically 
Biological experiments 2.5.1. Cells and cultures
Antiparasitic activity was performed with Leishmania amazonensis (MHOM/BR88/BA-125) and W2 strain Plasmodium falciparum, while hemolysis assays were done using O + human erythrocytes and cytotoxicity assays were done in J774 macrophages. The L. amazonensis promastigotes were maintained in Schneider's insect medium (SigmaAldrich, St. Louis, USA) supplemented with 10% fetal bovine serum (Gibco Laboratories, Gaithersburg, USA) and 50 μg/mL of gentamicin (Hipolabor, Belo Horizonte, Brazil). J774 macrophages were cultivated in RPMI-1640 medium (Sigma-Aldrich, St. Louis, USA) supplemented with 10% fetal bovine serum and 50 μg/mL of gentamicin. W2 strain P. falciparum was maintained in continuous culture of human erythrocytes (blood group O + ) using RPMI-1640 medium supplemented with 10% human plasma without hypoxanthine.
Cytotoxicity assays
J774 macrophages (5 × 10 4 cells/mL) were distributed in 96-well plate (100 μL/well) and incubated for 24 h at 37°C in 5% CO 2 . Each drug was solubilized in DMSO as a stock solution and diluted in culture media in the tested concentrations ranging from 0.1 to 10 μg/mL (100 μL/well). The final concentration of DMSO was 0.1%. Each concentration was tested in triplicate. After incubation for 72 h, 20 μL of Alamar blue (Invitrogen, CA, USA) was added to each well and incubated for 24 h in the dark. Gentian violet was used as control. The absorbance was evaluated at 570 and 600 nm according to manufacturer's instructions. The LC 50 values were calculated using a non-linear regression curve fit in the Prism version 5.03 (GraphPad Software). For the hemolysis assay, human erythrocytes type O + were washed three times in phosphate buffered saline and 100 μL of this suspension (1% hematocrit) was distributed into a 96-well plate. Then, 100 μL of each drug, previously dissolved in phosphate buffered saline, was added in triplicate to the plate and incubated for 1 h. Saponin (SigmaAldrich, St. Louis, USA) was used as reference drug at 1% v/v. After incubation the cells were centrifuged (1500 rpm for 10 min) and 100 μL of each supernatant was transferred to another microtiter plate. Released haemoglobin was monitored by measuring the absorbance at 540 nm in a spectrophotometer. The percentage of hemolysis was determined in comparison to untreated cells.
2.5.3.
Antileishmanial activity against promastigotes L. amazonensis promastigotes (2 × 10 6 cells/mL) in stationary growth phase were distributed in a 96-well plate (100 μL/well) at 24°C. Each drug was solubilized in DMSO as described above, diluted in the culture medium and added in serial dilution from 0.1 to 10 μg/mL (100 μL/well). The final DMSO concentration was 0.1%. Amphotericin B (Gibco Laboratories, Gaithersburg, USA) was used as reference drug. After 72 h incubation at 24°C, the number of viable parasites was counted in a Neubauer chamber. The IC 50 values were calculated in Prism version 5.03 (GraphPad Software) using non-linear regression.
In vitro leishmania infection J774 macrophages (2 × 10
5 cells/mL) were plated in 96-well plate (100 μL/well) and incubated overnight at 37°C in 5% CO 2 . L. amazonensis promastigotes in the stationary growth phase were added to the cell culture (100 μL/well) at a parasite/macrophage ratio of 10:1 and incubated for 24 h. Plates were washed to remove nonphagocytosed parasites. Each drug, solubilized as described above, was added and incubated for 72 h. Amphotericin B was used as reference drug. Infected macrophages were lysed by addition of 0.01% sodium dodecyl sulfate (Sigma-Aldrich, St. Louis, USA) in PBS (phosphate-buffered saline) at 37°C for 30 min.
Amastigotes from lysed macrophages were incubated at 24°C for 48 h, which then differentiated in promastigotes. The number of viable promastigotes was determined by adding Alamar Blue (20 μL/well) and incubated for 24 h. The absorbance was evaluated at 570 and 600 nm according to the manufacturer's instructions. The IC 50 values were calculated in Prism version 5.03 (GraphPad Software) using non-linear regression.
Antimalarial activity
The antimalarial effects of the compounds were measured with the [ 3 H]-hypoxanthine (PerkinElmer, Boston, USA) incorporation assay. W2 P. falciparum grown at 1-2% parasitemia and 2.5% hematocrit were aliquoted in a 96-well plate. Drugs were solubilized as described above in a concentration range of 0.1 to 10 μg/mL; each concentration was performed in triplicates. Mefloquine (Farmanguinhos, Rio de Janeiro, RJ, Brazil) was used as reference drug. After 24 h of incubation with the tested compounds, 25 μL of medium containing [ In this work the lapachol acted as bidentate ligand and monoanionic species, coordinating with the ruthenium atoms through its ortho oxygens (O1, O2- Fig. 1 ). The structures of the complexes [Ru(Lap)(PPh 3 ) 2 (bipy)]PF 6 (1) and [RuCl 2 (Lap)(dppb)] (5) were confirmed based on X-ray diffraction data (see Fig. 2 ). These compounds crystallize in the (5), showing atoms labeling and 50% of probability ellipsoids.
Table 2
Selected bond length (Ả) and angles (°) for complexes (1) and (5).
Fragment
Complex (1) Complex (5) Ru (1) 
76.22 (7) 77.85 ( monoclinic system, with the space group P2 1 /c. It is observed that the O1 and O2 atoms are involved in the coordination, where O2, is negatively charged and O1, is neutral. A distorted octahedral geometry is observed for both crystal structures, as observed by the bond angles (Table 2) . Some distance and selected angles in the X-ray structure of complex (1) and (5) are shown in Table 2 , which are, in general, in accordance with values expected for similar phosphine complexes of Ru(II) and Ru(III) for Ru-N, Ru-P and Ru-Cl [28] [29] [30] . But, it is interesting to point out that the distances of Ru(II)-O for complex (1) are also in accordance with the expected values, where the distance Ru-O2 [2.133(2) Ả] is longer than the distance Ru-O1 [2.0710(19) Ả], since the O2 has charge minus one and its radius is bigger than the one for the neutral species. Therefore, the same was not observed for complex (5) , where the distance Ru-O1 [2.1707(15) Ả] is longer than the distance Ru-O2 [2.0580(15) Ả]. Probably in this case the strong trans effect of phosphorus atoms is more effective when it is trans to neutral atoms, and not when it is trans to negatively charged atoms. As it can be seen in Table 2 Table 3 , and Fig. 3 for the case of complex (4). In the negative region a quasi-reversible oneelectron reduction process was observed in all cases, which most probably correspond to the ligand reduction to the semiquinone form [31] . As can be seen in Table 3 , respectively. This behavior was also observed for other complexes like Ru(II), Co(II), Ni(II) and Cu(II) containing the lapachol as ligand [5, 11, 12] . The characteristic ν(C 2 \O) stretching band found in 1028 cm −1 in the free lapachol shifted to higher frequencies in complexes (1065-1079 cm
−1
). Finally, new bands of medium intensities, located below 500 cm −1 are present in the spectra of complexes, which may be related to metal-ligand vibrations. The antiparasitic and toxicity of host cell were evaluated. For comparison, the metal-free lapachol was included in the pharmacological evaluation. Firstly, compounds were evaluated on their ability to inhibit the L. amazonensis promastigote proliferation, as well as against intracellular amastigotes, according to standard methodology [33] . Secondly, the antimalarial activity of the complexes was determined against the erythrocytic stage of W2 strain P. falciparum. Host cell cytotoxicity in J774 macrophages as well as the hemolysis in uninfected erythrocytes was determined [34, 35] . The results were expressed in terms of IC 50 and LC 50 values. Amphotericin B and mefloquine were respectively ). Table 4 Antiparasitic activity and cytotoxicity for the ruthenium complexes.
Compounds
L. amazonensis, IC 50 ± SEM(μM) P. falciparum 
Values determined 72 h after incubation with drugs.
Values determined for infected macrophages 72 h after incubation with drugs (c) Determined against W2 strain P. falciparum (erythrocytic stage) 24 h after incubation with drugs. used as reference drugs for Leishmania and Plasmodium tests respectively, while gentian violet was used as control in host cell cytotoxicity.
Amphotericin B, which was used as a reference drug, exhibited an IC 50 = 0.13 ± 0.01 μM, while lapachol was in practice, inactive against L. amazonensis promastigotes. Complex (1) was inactive to inhibit promastigotes, while complexes (2-5) were able to inhibit their proliferation. Specifically, complexes (2) and (5) exhibited activity against promastigotes similar to the observed for amphotericin B. Regarding the inhibitory activity in L. amazonensis-infected macrophages, amphotericin B displayed an IC 50 = 0.23 ± 0.09 μM, while lapachol was inactive. In this assay, complexes (3) and (4) were also inactive. In contrast, complexes (1), (2) and (5) were able to reduce the Leishmania infection in macrophages, with similar potency to the observed for amphotericin B.
The cytotoxicity towards host cells was also determined for all five complexes, including lapachol. Gentian violet had a LC 50 = 0.60 ± 0.07, while lapachol was non-toxic, having a LC 50 N 10 μM for J774 macrophages. In comparison to lapachol, complexes (1-4) were more cytotoxic, while complex (5) was not cytotoxic. The selectivity index was calculated and shown in Table 4 . Considering the antileishmania activity, complex (5) exhibited high selectivity index, while complexes (1-2) showed indexes lower than complex (5) .
Next, the antimalarial activity for these complexes was evaluated. Lapachol displayed a weak activity to inhibit P. falciparum in comparison to mefloquine. It was observed that complex (1) showed a poor activity, while the complexes (2-5) were several times more potent than free lapachol. The most potent complexes against P. falciparum were (4) and (5). These complexes were fifty times more potent than free lapachol and only five times less potent than mefloquine. In addition, the effects of complexes (1-5), as well as of free lapachol, in causing hemolysis were evaluated and the percentage of hemolysis was calculated. Saponin, was used as the reference drug to cause hemolysis to the erythrocytes (Fig. 4) . Lapachol did not cause hemolysis. The complexes (1-5) failed to cause not even 50% of hemolysis at 200 μM. This suggests that the reported anti-P. falciparum activity was not caused by the red blood cells lyses.
Conclusions
In summary, five new ruthenium (II) and (III) complexes containing lapachol as ligand were synthesized and characterized by a combination of NMR, EPR, FTIR, and X ray diffraction techniques. The evaluation of antiparasitic activities of the complexes against L. amazonensis and P. falciparum demonstrated that the lapachol-ruthenium complexes are more potent than the free lapachol. The [RuCl 2 (Lap)(dppb)] complex is the most potent and selective antiparasitic compound among the five new ruthenium complexes studied in this work, exhibiting an activity comparable to the one of reference drugs. Specifically, lapachol-ruthenium complexes displayed potent and selective antileishmanial activity.
